Abstract: The present invention relates to a compound of formula (I); wherein R1 represents isopropyl or trifluoromethyl; R2 represents hydrogen, C1-4alkyl, chloro, fluoro or trifluoromethyl; R3 represents(i) phenyl, optionally substituted by cyano, halogen, trifluoromethyl or an optionally substituted 5-membered heteroaromatic group, where optional substitution is effected by C1-4alkyl, (ii) a 5-membered heteroaromatic group, optionally substituted by halogen, cyano or C1-4alkyl, (ii) aminocabonyl, or(iv) ethyl or eth-1-enyl; R4 represents cyano, methyl, acetyl, a 5-membered heteoaromatic group, optionally substituted by C1-4alkyl or phenyl or a group X—Y-Z; X represents a carboxy, oxo, C1-6alkylene, carboxamido or thiocarboxamido linking group; Y represents a direct link or C1-4alkylene, Z represents (i) hydrogen, (ii) trifluoromethyl, (iii) cyano, (iv) phenyl (v) a 5- or 6-membered heteroaromatic group, optionally substituted by C1-4alkyl, with the proviso that when X represents C1-4alkylene, Y and Z do not re

Abstract: The present invention relates to A compound of formula (I) wherein A, U, V, X, Z, R1, Y, R2 and R3 are defined in the description or a physiologically acceptable salt, solvate or derivative thereof, to compositions and processes for making said compounds and their use in treating conditions ameliorated by an apoB-100 and/or MTP inhibitor.

Abstract: Compounds are described of general formula (I) ##STR1## and salts and solvates thereof, including physiologically acceptable salts and solvates thereof, in which:Z represents either Het, ##STR2## Het represents an optionally substituted bicyclic or tricyclic ring selected from acricine isoquinolin-1-yl, isoquinolin-3-yl,The novel compounds of formula (I) can sensitize multi-drug resistant cancer cells to chemotherapeutic agents and may be formulated for use in therapy, particularly to improve or increase the efficacy of an anti-tumour drug.

Abstract: These are provided compounds of formula I ##STR1## wherein A represents an oxygen or a sulphur atom, a bond or a group (CH.sub.2).sub.1 NR.sup.9 (where 1 represents zero or 1 and R.sup.9 represents a hydrogen atom or a methyl group); B represents a C.sub.1-4 alkylene chain optionally substituted by a hydroxyl group, except that the hydroxyl group and moiety A can not be attached to the same carbon atom when A represents an oxygen or sulphur atom or a group (CH.sub.2).sub.1 NR.sup.9, or when A represents a bond B may also represent a C.sub.2-4 alkenylene chain; R.sup.3 represents a hydrogen atom or a C.sub.1-4 alkyl group; m represents 1 or 2; R.sup.7 represents a hydrogen atom or R.sup.3 and R.sup.7 together form a group --(CH.sub.2).sub.n -- where n represents 1 or 2. These compounds can sensitize multidrug-resistant cancer cells to chemotherapeutic agents and may be formulated for use in therapy, particularly to improve or increase the efficacy of an antitumor drug.